A phase 2, adaptive randomized, double-blind, placebo-controlled, multicenter, 52-week study of HM15211 in patients with biopsy-confirmed non-alcoholic steatohepatitis - Study design and rationale of HM-TRIA-201 study
GLP-1 receptors aren't just found in the gut and pancreasthey're also present in areas of the brain involved in reward and addiction
AMRFinderPlus and the Reference Gene Catalog facilitate examination of the genomic links among antimicrobial resistance, stress response, and virulence
Peptide degradation from temperature excursions can occur without any visible change to the solution, meaning a compromised product may appear normal
The most common adverse events were gastrointestinal, and the vast majority were mild to moderate and diminished over time, consistent with the GLP-1 receptor agonist class
, ,